0000880771-16-000173.txt : 20160816 0000880771-16-000173.hdr.sgml : 20160816 20160816144332 ACCESSION NUMBER: 0000880771-16-000173 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160812 FILED AS OF DATE: 20160816 DATE AS OF CHANGE: 20160816 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cheung Wilson Wai-Shun CENTRAL INDEX KEY: 0001291656 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 161835752 MAIL ADDRESS: STREET 1: SCICLONE PHARMACEUTICALS, INC. STREET 2: 950 TOWER LANE, SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 certent-form4.xml PRIMARY DOCUMENT X0306 4 2016-08-12 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001291656 Cheung Wilson Wai-Shun 950 TOWER LANE, SUITE 900 FOSTER CITY CA 94404 0 1 0 0 CFO & Senior VP, Finance Common Stock 2016-08-12 4 M 0 25000 0 A 25000 D Common Stock 2016-08-12 4 M 0 12500 0 A 37500 D Common Stock 2016-08-12 4 M 0 3000 0 A 40500 D Common Stock 2016-08-12 4 F 0 9396 10.41 D 31104 D Common Stock 2016-08-12 4 F 0 1128 10.41 D 29976 D Common Stock 2016-08-12 4 F 0 4698 10.41 D 25278 D Common Stock 2016-08-16 4 S 0 7802 10.6174 D 17476 D Restricted Stock Unit 2016-08-12 4 A 0 30000 0 A Common Stock 30000 229000 D Restricted Stock Unit 2016-08-12 4 M 0 25000 0 D Common Stock 25000 204000 D Restricted Stock Unit 2016-08-12 4 M 0 12500 0 D Common Stock 12500 191500 D Restricted Stock Unit 2016-08-12 4 M 0 3000 0 D Common Stock 3000 188500 D Shares disposed represent shares withheld to cover withholding tax obligations in connection with the vesting of Restricted Stock Units. Granted under the Issuer's 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock. Each RSU will vest and be settled on August 15, 2017, subject to the reporting person's continued employment, but will terminate upon the occurrence of a change in control on or before March 31, 2017. Granted under the Issuer's 2005 Equity Incentive Plan. Provided Reporting Person remains employed by the Issuer, 33.33% of the restricted stock units vested on January 4, 2016, 33.33% will vest on January 3,2017, and 33.34% will vest on January 2, 2017, unless the trading window is closed for the Reporting Person on such date, in which case the vesting date will be deferred until the next date that the trading window is open. Provided Reporting Person remains employed by the Issuer, 25% of the restricted stock units will vest on each August 9, 2014, August 9, 2015, August 9, 2016, and August 9, 2017, unless the trading window is closed for the Reporting Person on such date, in which case the vesting date will be deferred until the next date that the trading window is open. Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment. /s/ Wilson W. Cheung 2016-08-16